Adaptive Biotechnologies Corp (ADPT)

$14.09 +0.56 (4.14%)
Market Cap 2.24B
Revenue (ttm) 276.98M
Net Income (ttm) -59.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -21.48%
Debt to Equity Ratio 0.00
Volume 1,189,350
Avg Vol 1,915,236
Day's Range N/A - N/A
Shares Out 159.76M
Stochastic %K 16%
Beta 2.29
Analysts Strong Sell
Price Target $20.57

Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient'...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 659 0067
Fax: 206 659 0667
Address:
1165 Eastlake Avenue East, Seattle, United States
WallStreetBuyDip
WallStreetBuyDip Apr. 27 at 10:12 AM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
1 · Reply
LewisDaKat
LewisDaKat Apr. 18 at 3:30 PM
$ADPT Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? https://marketwirenews.com/stock/adpt/news/should-you-sell-adaptive-biotechnologies-adpt-after--7270779698440434.html?utm_source=stocktwits
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 12 at 9:18 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Treasury225
Treasury225 Apr. 9 at 5:03 PM
$ADPT getting pretty F’ing sick of holding on to this while insiders beat it down soon as it gets traction. EVENTUALLY the excuses for insider selling runs out.
0 · Reply
Joncook642
Joncook642 Apr. 8 at 1:09 PM
$ADPT Glad I bought in when it was down😉. Big home run with this one!
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 3 at 4:17 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Treasury225
Treasury225 Mar. 27 at 7:54 PM
$ADPT don’t have to be a technician to figure this one out.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 24 at 6:55 PM
$ADPT Share Price: $13.80 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.25 – $1.53 Potential Upside: 55% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 22 at 8:13 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Treasury225
Treasury225 Mar. 20 at 9:03 PM
$ADPT Interesting close volume wise…. Looks good for monday
0 · Reply
Latest News on ADPT
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

Apr 15, 2026, 4:05 PM EDT - 15 days ago

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

Adaptive Biotechnologies Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:50 AM EST - 2 months ago

Adaptive Biotechnologies Transcript: TD Cowen 46th Annual Health Care Conference

Adaptive Biotechnologies Earnings Call Transcript: Q4 2025

Feb 5, 2026, 4:30 PM EST - 2 months ago

Adaptive Biotechnologies Earnings Call Transcript: Q4 2025

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 5, 2026, 4:05 PM EST - 3 months ago

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Jan 27, 2026, 4:05 PM EST - 3 months ago

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

Jan 22, 2026, 4:05 PM EST - 3 months ago

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

Adaptive Biotechnologies Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 PM EST - 3 months ago

Adaptive Biotechnologies Transcript: 44th Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Jan 12, 2026, 7:30 AM EST - 3 months ago

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech

Jan 6, 2026, 11:51 AM EST - 4 months ago

Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 30, 2025, 4:05 PM EST - 4 months ago

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

Dec 15, 2025, 8:24 AM EST - 4 months ago

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

PFE

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Dec 15, 2025, 8:00 AM EST - 4 months ago

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

PFE

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

Dec 9, 2025, 5:07 PM EST - 5 months ago

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Dec 6, 2025, 8:30 AM EST - 5 months ago

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Dec 5, 2025, 1:33 PM EST - 5 months ago

Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Adaptive Biotechnologies Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:30 AM EST - 5 months ago

Adaptive Biotechnologies Transcript: Piper Sandler 37th Annual Healthcare Conference

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Nov 24, 2025, 7:30 AM EST - 5 months ago

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Adaptive Biotechnologies Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 3:00 AM EST - 5 months ago

Adaptive Biotechnologies Transcript: Jefferies London Healthcare Conference 2025

Adaptive Biotechnologies Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 6 months ago

Adaptive Biotechnologies Earnings Call Transcript: Q3 2025

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 6 months ago

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 15, 2025, 4:05 PM EDT - 7 months ago

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

Adaptive Biotechnologies Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 1:05 PM EDT - 8 months ago

Adaptive Biotechnologies Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 27, 2025, 4:05 PM EDT - 8 months ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Adaptive Biotechnologies Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 9 months ago

Adaptive Biotechnologies Earnings Call Transcript: Q2 2025

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 4:05 PM EDT - 9 months ago

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 15, 2025, 4:05 PM EDT - 10 months ago

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Jul 1, 2025, 7:30 AM EDT - 10 months ago

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Adaptive Biotechnologies Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 8:40 AM EDT - 11 months ago

Adaptive Biotechnologies Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

May 30, 2025, 7:30 AM EDT - 11 months ago

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Adaptive Biotechnologies Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Adaptive Biotechnologies Earnings Call Transcript: Q1 2025

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 10, 2025, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Adaptive Biotechnologies Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:10 AM EST - 1 year ago

Adaptive Biotechnologies Transcript: TD Cowen 45th Annual Healthcare Conference

Adaptive Biotechnologies Earnings Call Transcript: Q4 2024

Feb 11, 2025, 4:30 PM EST - 1 year ago

Adaptive Biotechnologies Earnings Call Transcript: Q4 2024

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Jan 22, 2025, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Adaptive Biotechnologies Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 8:15 PM EST - 1 year ago

Adaptive Biotechnologies Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Jan 14, 2025, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Jan 7, 2025, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Dec 7, 2024, 6:30 PM EST - 1 year ago

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Dec 3, 2024, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Adaptive Biotechnologies Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Adaptive Biotechnologies Earnings Call Transcript: Q3 2024

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Nov 7, 2024, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 9, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Adaptive Biotechnologies Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 6, 2024, 12:20 PM EDT - 1 year ago

Adaptive Biotechnologies Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Aug 29, 2024, 7:30 AM EDT - 1 year ago

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 4:03 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Adaptive Biotechnologies Earnings Call Transcript: Q2 2024

Aug 1, 2024, 4:30 PM EDT - 1 year ago

Adaptive Biotechnologies Earnings Call Transcript: Q2 2024

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Adaptive Biotechnologies Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 11, 2024, 1:20 PM EDT - 2 years ago

Adaptive Biotechnologies Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 31, 2024, 7:30 AM EDT - 2 years ago

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 29, 2024, 4:05 PM EDT - 2 years ago

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Adaptive Biotechnologies Earnings Call Transcript: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q1 2024

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

May 7, 2024, 4:05 PM EDT - 2 years ago

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 17, 2024, 4:05 PM EDT - 2 years ago

Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

Adaptive Biotechnologies Transcript: Status Update

Apr 2, 2024, 4:30 PM EDT - 2 years ago

Adaptive Biotechnologies Transcript: Status Update

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

Apr 2, 2024, 4:05 PM EDT - 2 years ago

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

Mar 27, 2024, 8:30 AM EDT - 2 years ago

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

Adaptive Biotechnologies Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 2:10 PM EST - 2 years ago

Adaptive Biotechnologies Transcript: TD Cowen 44th Annual Health Care Conference 2024

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

Feb 22, 2024, 4:05 PM EST - 2 years ago

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

Adaptive Biotechnologies Earnings Call Transcript: Q4 2023

Feb 14, 2024, 4:30 PM EST - 2 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q4 2023

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 4:05 PM EST - 2 years ago

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

Jan 29, 2024, 4:05 PM EST - 2 years ago

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

Adaptive Biotechnologies Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 4:30 PM EST - 2 years ago

Adaptive Biotechnologies Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 27, 2023, 4:05 PM EST - 2 years ago

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

Dec 9, 2023, 8:30 AM EST - 2 years ago

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

Dec 5, 2023, 7:30 AM EST - 2 years ago

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

Adaptive Biotechnologies Earnings Call Transcript: Q3 2023

Nov 9, 2023, 4:30 PM EST - 2 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q3 2023

Adaptive Biotechnologies Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 13, 2023, 1:35 PM EDT - 2 years ago

Adaptive Biotechnologies Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Adaptive Biotechnologies Earnings Call Transcript: Q2 2023

Aug 2, 2023, 4:30 PM EDT - 2 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q2 2023

Adaptive Biotechnologies Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

Jun 12, 2023, 7:00 PM EDT - 3 years ago

Adaptive Biotechnologies Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

Adaptive Biotechnologies Earnings Call Transcript: Q1 2023

May 3, 2023, 4:30 PM EDT - 3 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q1 2023

Adaptive Biotechnologies Earnings Call Transcript: Q4 2022

Feb 14, 2023, 4:30 PM EST - 3 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q4 2022

Adaptive Biotechnologies Transcript: JPMorgan Healthcare Conference

Jan 9, 2023, 4:30 PM EST - 3 years ago

Adaptive Biotechnologies Transcript: JPMorgan Healthcare Conference

Adaptive Biotechnologies Earnings Call Transcript: Q3 2022

Nov 3, 2022, 4:30 PM EDT - 3 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q3 2022

Adaptive Biotechnologies Earnings Call Transcript: Q2 2022

Aug 3, 2022, 2:38 AM EDT - 4 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q2 2022

Adaptive Biotechnologies Earnings Call Transcript: Q1 2022

May 4, 2022, 5:52 AM EDT - 4 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q1 2022

Adaptive Biotechnologies Earnings Call Transcript: Q4 2021

Feb 15, 2022, 9:11 AM EST - 4 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q4 2021

Adaptive Biotechnologies Earnings Call Transcript: Q3 2021

Nov 2, 2021, 8:00 PM EDT - 4 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q3 2021

Adaptive Biotechnologies Earnings Call Transcript: Q2 2021

Aug 4, 2021, 3:25 PM EDT - 5 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q2 2021

Adaptive Biotechnologies Earnings Call Transcript: Q1 2021

May 4, 2021, 7:38 PM EDT - 5 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q1 2021

Adaptive Biotechnologies Earnings Call Transcript: Q4 2020

Feb 24, 2021, 4:30 PM EST - 5 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q4 2020

Adaptive Biotechnologies Earnings Call Transcript: Q3 2020

Nov 10, 2020, 4:30 PM EST - 5 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q3 2020

Adaptive Biotechnologies Earnings Call Transcript: Q2 2020

Aug 10, 2020, 4:30 PM EDT - 6 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q2 2020

Adaptive Biotechnologies Earnings Call Transcript: Q1 2020

May 12, 2020, 4:30 PM EDT - 6 years ago

Adaptive Biotechnologies Earnings Call Transcript: Q1 2020

WallStreetBuyDip
WallStreetBuyDip Apr. 27 at 10:12 AM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
1 · Reply
LewisDaKat
LewisDaKat Apr. 18 at 3:30 PM
$ADPT Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? https://marketwirenews.com/stock/adpt/news/should-you-sell-adaptive-biotechnologies-adpt-after--7270779698440434.html?utm_source=stocktwits
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 12 at 9:18 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Treasury225
Treasury225 Apr. 9 at 5:03 PM
$ADPT getting pretty F’ing sick of holding on to this while insiders beat it down soon as it gets traction. EVENTUALLY the excuses for insider selling runs out.
0 · Reply
Joncook642
Joncook642 Apr. 8 at 1:09 PM
$ADPT Glad I bought in when it was down😉. Big home run with this one!
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 3 at 4:17 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Treasury225
Treasury225 Mar. 27 at 7:54 PM
$ADPT don’t have to be a technician to figure this one out.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 24 at 6:55 PM
$ADPT Share Price: $13.80 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.25 – $1.53 Potential Upside: 55% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 22 at 8:13 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Treasury225
Treasury225 Mar. 20 at 9:03 PM
$ADPT Interesting close volume wise…. Looks good for monday
0 · Reply
RunnerSignals
RunnerSignals Mar. 14 at 8:06 AM
$ADPT reclaiming momentum from $12.45 support. RSI 32 and volume 3.9M vs 2.0M avg. accumulation visible. outlook: positive
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 13 at 5:52 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
nickmick
nickmick Mar. 12 at 6:37 PM
$ADPT Accumulating! Solid business model, conservative guidance, take-over target, completely oversold. Ty!
1 · Reply
Treasury225
Treasury225 Mar. 12 at 6:15 PM
$ADPT ya gotta think if there is a stock that is immune to the escalating war issues it’s ADPT. Feels like the covid market… Sell everything and wait. The company is MUM so maybe there’s something more specific but this chart sucks.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 2:27 AM
$ADPT RSI: 53.27, MACD: -0.3197 Vol: 0.88, MA20: 16.21, MA50: 16.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 9:28 PM
$ADPT Current Stock Price: $16.11 Contracts to trade: $15.0 ADPT Mar 20 2026 Call Entry: $1.03 Exit: $1.48 ROI: 43% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
1AlwaysBull1
1AlwaysBull1 Mar. 2 at 8:37 PM
$ADPT i'm in for a swing
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 2 at 2:32 PM
$ADPT Share Price: $15.71 Contract Selected: Oct 16, 2026 $20 Calls Buy Zone: $1.99 – $2.46 Target Zone: $3.61 – $4.41 Potential Upside: 71% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 26 at 6:09 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Joncook642
Joncook642 Feb. 25 at 2:07 PM
$ADPT Gonna be a good day for the whole market 😉
0 · Reply
Joncook642
Joncook642 Feb. 18 at 2:06 PM
$ADPT Guidance is to low. Gonna beat for the next 3 quarters. I’m in now😉
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 14 at 4:31 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply